论文部分内容阅读
目的探讨50例肾移植患者术后血清红细胞生成素(SEP)的变化,进一步了解它与血红蛋白、血肌酐变化的关系。方法采用酶标法对肾移植患者术后1、2、3、4周进行血清红细胞生成素的测定,同时测定血常规、肾功能等。并将其中18例使用人类基因重组红细胞生成素(rHuEpo)者,和18例未使用者,作了对照研究。结果肾移植术后 SEP 的活性增高,同时伴随着血红蛋白上升,两者间呈正相关系(P=0.002),血肌酐下降越明显者,则 SEP 增高越明显,两者间呈负相关系(P<0.05)。术前使用或未使用 rHuEpo 对术后 SEP 无明显影响(P>0.05)。结论测定 SEP 活性的高低,动态观察其变化趋势,对估计和监测肾移植后的排异反应及治疗效果和判断预后有价值。
Objective To investigate the changes of postoperative serum levels of erythropoietin (SEP) in 50 patients with renal allograft and further investigate its relationship with hemoglobin and serum creatinine. Methods The enzyme-linked immunosorbent assay (ELISA) was used to determine the serum levels of erythropoietin in patients with renal allografts at 1, 2, 3, and 4 weeks after operation. The blood routine and renal function were also measured. In addition, 18 cases of human recombinant human erythropoietin (rHuEpo) and 18 cases of non-users were compared. Results After SEP, the activity of SEP was increased, accompanied by the increase of hemoglobin, the positive correlation was found between them (P = 0.002). The more significant the decline of serum creatinine was, the more significant the SEP was. <0.05). Preoperative SEP with or without rHuEpo had no significant effect (P> 0.05). Conclusion The determination of the level of SEP activity, dynamic observation of its trends, the evaluation and monitoring of renal transplant rejection and treatment and prognosis of prognosis.